Close Menu

NEW YORK — Progenity on Friday priced its planned initial public offering of 6,666,667 shares of its common stock at $15 per share, making the transaction worth $100 million.

The Ann Arbor, Michigan-based molecular diagnostics testing lab has also granted the underwriters of the offering — Piper Sandler, Wells Fargo Securities, Robert W. Baird, Raymond James, and BTIG — a 30-day option to purchase an additional 1,000,000 shares at the offering price, which would raise another $15 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.